

CITATION REPORT

List of articles citing

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

DOI: PM/1972347

Cancer Research, 1990, 50, 4087-91.

Source: <https://exaly.com/paper-pdf/126809339/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
552	Gynecologic tumor markers. 1990 , 6, 305-13		14
551	The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. 1990 , 5, 55-61		102
550	Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. 1991 , 165, 640-6		58
549	Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 1991 , 164, 15-21		229
548	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. 1991 , 164, 669-74		182
547	Ovarian cancer. Advances in management. 1991 , 71, 1023-39		7
546	Diagnostic utility of oncogenes and their products in human cancer. 1991 , 1072, 193-214		8
545	An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia. <i>International Journal of Gynecological Cancer</i> , 1991 , 1, 285-289	3.5	14
544	Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. 1991 , 49, 44-9		222
543	The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 1991 , 49, 323-8		269
542	Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. 1991 , 4, 189-95		48
541	Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. 1991 , 11, 117-27		252
540	Abstracts. 1991 , 9, 343-399		3
539	Oncogenes in gynecological tumors. 1992 , 85, 357-72		7
538	The genetics of ovarian cancer. 1992 , 10, 135-41		9
537	Unsettled questions regarding ovarian cancer. 1992 , 155, 7-18		3
536	Oncogenesis in ovarian cancer. 1992 , 155, 25-30		18

535	Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and proto-oncogenes. 1992 , 16, 439-49		13
534	The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. 1992 , 167, 1877-82		6
533	Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. 1992 , 28, 322-6		5
532	Hormonal therapy for stomach cancer. 1992 , 39, 137-9		12
531	Applications of image cytometry in the diagnostic laboratory. 1992 , 12, 41-48		
530	NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. 1992 , 44, 245-53		62
529	Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. 1992 , 166, 676-84		85
528	Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. 1992 , 61, 95-103		73
527	Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. 1992 , 23, 1141-50		51
526	Genetic changes in epithelial ovarian neoplasia. 1992 , 47, 135-6		4
525	HER-2/neu expression: a major prognostic factor in endometrial cancer. 1992 , 47, 179-85		195
524	Ha-ras polymorphisms in epithelial ovarian cancer. 1992 , 45, 299-302		1
523	Tumor cell heterogeneity: an overview. 1992 , 206, 3-7		8
522	Prognostic Factors in Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 761-781	3.1	19
521	Growth Regulation of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 829-841	3.1	21
520	Oncogenes in Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 813-827	3.1	16
519	Biologic and Immunologic Therapy of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 941-965	3.1	9
518	Specific detection of c-erbB-2 mRNA expression in gastric cancers by the polymerase chain reaction following reverse transcription. 1992 , 66, 84-7		17

517	Prognostic impact of chromosome aberrations in ovarian cancer. 1992 , 65, 282-6	25
516	Ovarian cancer, Part I: Biology. 1992 , 16, 1-57	63
515	Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta. 1992 , 420, 385-93	29
514	Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. 1992 , 421, 393-400	34
513	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. 1992 , 24, 85-95	596
512	Chromosome aberrations in 35 primary ovarian carcinomas. 1992 , 4, 58-68	113
511	Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. 1992 , 50, 64-8	28
510	Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. 1992 , 52, 218-24	54
509	Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. 1992 , 52, 311-6	18
508	Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. 1992 , 5, 213-8	100
507	Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. 1992 , 69, 1607-32	29
506	Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. 1992 , 70, 2857-60	32
505	Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. 1993 , 71, 3942-6	71
504	Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. 1993 , 72, 2433-40	140
503	Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. 1993 , 72, 2628-37	48
502	Cellular oncogenes and suppressor genes as prognostic markers in cancer. 1993 , 26, 439-47	34
501	Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 1993 , 53, 401-8	52
500	Cell growth regulation in epithelial ovarian cancer. 1993 , 71, 1597-601	66

499	Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. 1993 , 37, 255-63	414
498	Die Bedeutung der c-erbB-2 und c-myc Onkogen-Expression für die Prognose beim Ovarialkarzinom. 1993 , 254, 946-948	
497	Immunhistochemische Untersuchungen über das c-erbB-2 Protein am Ovarialkarzinom. 1993 , 254, 951-952	
496	Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. 1993 , 168, 162-9	108
495	neu mutations and loss of normal allele in schwannomas induced by N-ethyl-N-nitrosourea in rats. 1993 , 70, 45-50	7
494	The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 1993 , 168, 228-32	28
493	What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. 1993 , 189, 1233-52	20
492	Double minutes are frequently found in ovarian carcinomas. 1993 , 71, 125-31	14
491	Cytogenetic studies of epithelial ovarian carcinoma. 1993 , 71, 76-86	65
490	p53 accumulation in ovarian carcinomas and its prognostic implications. 1993 , 24, 1175-9	94
489	Tumour markers. 1993 , 4, S71-S77	30
488	Cancer of the ovary. 1993 , 329, 1550-9	313
487	Human-specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. 1993 , 78, 240-51	24
486	Molecular and biological factors in the pathogenesis of ovarian cancer. 1993 , 4 Suppl 4, 3-16	9
485	Overexpression of p185 is not related to erbB2 amplification in ovarian cancer. 1993 , 4, 775-9	6
484	Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies. 1993 , 8, 233-239	4
483	Molecular analysis of bivalve tumors: models for environmental/genetic interactions. 1994 , 102 Suppl 12, 81-3	24
482	Pathogenesis of ovarian cancers. 1994 , 1, 181-90	36

481	Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. 1994 , 47, 914-9	57
480	Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity. 1994 , 39, 318-24	7
479	Etiology, biology, and epidemiology of ovarian cancer. 1994 , 10, 242-8	29
478	Calcium-mediated signal transduction: biology, biochemistry, and therapy. 1994 , 13, 31-44	79
477	Infrequent transforming mutations in the transmembrane domain of the neu oncogene in spontaneous rat schwannomas. 1994 , 9, 230-5	3
476	Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. 1994 , 73, 1456-9	63
475	Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. 1994 , 73, 1460-6	51
474	Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. 1994 , 73, 1882-8	143
473	Interferon gamma-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells. 1994 , 58, 538-42	5
472	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. 1994 , 59, 242-7	14
471	Immunohistochemical characterization of undifferentiated carcinomas of the ovary. 1994 , 120, 672-7	25
470	Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. 1994 , 120, 378-81	33
469	Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. 1994 , 85, 1247-56	49
468	Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. 1994 , 25, 1075-83	88
467	Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. 1994 , 170, 1177-83	72
466	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. 1994 , 170, 1285-96	27
465	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. 1994 , 170, 1285-1296	28
464	In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. 1995 , 4, 41-9	13

463	Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. 1995 , 75, 2147-52	103
462	c-erbB-2 and p53 expression in fallopian tube carcinoma. 1995 , 75, 2891-6	33
461	Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium. 1995 , 76, 650-7	62
460	The molecular basis of ovarian cancer. 1995 , 76, 1992-7	45
459	Molecular basis of endometrial cancer. 1995 , 76, 2034-40	84
458	c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. 1995 , 63, 604-8	33
457	c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. 1995 , 64, 146-51	71
456	c-erbB growth-factor-receptor proteins in ovarian tumours. 1995 , 64, 202-6	42
455	Biomarkers in the ovary. 1995 , 59, 223-226	18
454	Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?. 1995 , 23, 227-32	10
453	Immunity to oncogenic proteins. 1995 , 145, 33-59	153
452	c-erbB-3 protein expression in ovarian tumours. 1995 , 71, 758-62	32
451	Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. 1995 , 72, 691-5	30
450	c-erbB-2 oncogene expression in Stage I epithelial ovarian cancer. 1995 , 102, 65-7	5
449	Epidermal growth factor-related peptides and their receptors in human malignancies. 1995 , 19, 183-232	2150
448	Selective inhibition of the tyrosine kinase pp60src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one. 1995 , 5, 1007-1010	27
447	Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. 1995 , 17, 15-21	51
446	An evaluation of prognostic factors in advanced ovarian cancer. 1995 , 63, 115-24	7

445	HER-2/neu-targeting gene therapy--a review. 1995 , 159, 65-71	58
444	EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. 1995 , 21, 167-78	27
443	Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. 1995 , 34, 499-504	73
442	Genetic changes in ovarian cancer. 1995 , 27, 73-8	54
441	An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. 1995 , 31A, 2248-54	11
440	Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. 1995 , 21, 56-60	22
439	Basic fibroblast growth factor and ovarian cancer. 1995 , 53, 375-9	26
438	mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. 1995 , 89, 63-71	12
437	Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. 1996 , 15, 749-57	11
436	Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. 1996 , 27, 1324-8	42
435	Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. 1996 , 98, 151-155	23
434	The biochemistry of metastasis. 1996 , 32, 135-66	34
433	The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. 1996 , 59, 441-7	13
432	Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. 1996 , 74, 1749-56	154
431	The Role of the HER-2/neu Oncogene in Gynecologic Cancers. 1996 , 3, 99-105	2
430	Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. 1996 , 74, 1427-33	16
429	c-erbB3 protein expression in ovarian cancer. 1996 , 49, M199-202	26
428	Immunohistochemical study of c-erb B-2 expression in malignant mixed mllerian tumors of the female genital tract. 1996 , 22, 347-51	8

427	Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. 1996 , 61, 100-5	33
426	Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. 1996 , 178, 140-5	13
425	Expression of cell regulatory proteins in ovarian borderline tumors. 1996 , 77, 2092-8	20
424	ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. 1996 , 16, 130-7	18
423	Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. 1996 , 18, 185-98	10
422	HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. 1996 , 271, 4813-8	70
421	Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. 1996 , 24, 4558-64	26
420	Transforming Growth Factor-alpha and c-erbB-2 Oncogene Products in Ovarian Epithelial Tumors. 1996 , 4, 129-135	
419	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. 1997 , 7, 391-417	25
418	Bispecific antibodies for the treatment of tumours and infectious diseases. 1997 , 6, 1169-78	1
417	Immunoliposomes for cancer treatment. 1997 , 40, 399-435	78
416	Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. 1997 , 272, 27913-8	182
415	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. 1997 , 18, 435-61	100
414	HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. 1997 , 71, 343-71	119
413	Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. 1997 , 75, 1256-62	44
412	The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. 1997 , 75, 315-325	56
411	Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities. 1997 , 53, 287-98	9
410	Human ovarian cancer of the surface epithelium. 1997 , 54, 541-4	73

409	Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity. 1997 , 231, 251-9	6
408	Overexpression of cyclin D1 in epithelial ovarian cancers. 1997 , 64, 189-95	89
407	p53 and HER-2/neu overexpression in ovarian borderline tumors. 1997 , 65, 218-24	31
406	Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. 1997 , 66, 85-8	15
405	Radioiodinated antibody targeting of the HER-2/neu oncoprotein. 1997 , 24, 451-459	14
404	Epithelial ovarian carcinoma. 1997 , 349, 113-7	121
403	Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. 1997 , 71, 173-9	92
402	Inducible antisense inhibition of erbB-2 expression reduces anchorage independent growth of ovarian carcinoma cells. 1997 , 117, 73-9	7
401	Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. 1997 , 121, 169-75	109
400	Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. 1997 , 75, 1782-7	58
399	Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. 1997 , 76, 77-82	19
398	Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. 1997 , 47, 179-82	11
397	Molecular profile of advanced-stage transitional cell carcinoma of the ovary. 1997 , 177, 120-5	9
396	Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. 1997 , 66, 449-53	10
395	Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. 1997 , 259, 189-95	21
394	Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary. 1997 , 33, 325-31	19
393	Estrogen action in human ovarian cancer. 1997 , 25, 1-9	67
392	A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. 1997 , 79, 1587-1594	44

391	Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. 1997 , 79, 2147-53	12
390	Vascular endothelial growth factor expression in early stage ovarian carcinoma. 1997 , 80, 98-106	323
389	Alteration of p16 and p15 genes in common epithelial ovarian tumors. 1997 , 74, 148-55	36
388	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. 1998 , 17, 195-202	25
387	Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. 1998 , 70, 49-55	4
386	Amplification and expression of the c-erbB-2 oncogene in Mullerian-derived genital-tract tumors. 1998 , 71, 165-71	6
385	Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. 1998 , 70, 378-85	55
384	Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. 1998 , 89, 903-9	20
383	Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. 1998 , 77, 1405-12	173
382	Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. 1998 , 30, 219-227	27
381	The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. 1998 , 1377, M25-37	72
380	Prognostic significance of c-erbB-2 oncoprotein expression in intestinal-type adenocarcinoma of the sinonasal tract. 1998 , 20, 224-31	25
379	Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for B cell tumour antigens. 1998 , 93, 192-9	48
378	c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. 1998 , 132, 91-7	15
377	Isolation and characterization of mouse ovarian surface epithelial cell lines. 1998 , 194, 725-30	17
376	Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. 1998 , 29, 34-40	69
375	c-erbB-2 as a target for immunotherapy. 1998 , 7, 1879-96	4
374	Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element. 1998 , 246, 353-8	3

373	Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. 1998 , 77, 85-90	19
372	A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. 1998 , 9, 1775-98	40
371	Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. 1998 , 17, 313-21	27
370	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. 1998 , 8, 425-442	18
369	C-erbB-2 Expression in Primary Breast Cancer. 1999 , 14, 16-26	19
368	Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?. 1999 , 10, S9-S15	6
367	A role for intracellular immunization in chemosensitization of tumor cells?. 1999 , 6, 1202-9	6
366	Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. 1999 , 81, 790-5	6
365	HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. 1999 , 66, 163-9	36
364	Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. 1999 , 67, 135-43	31
363	Analysis of protooncogene c-erbB-2 in benign and malignant human prostate. 1999 , 31, 61-73	11
362	American Joint Committee on Cancer prognostic factors consensus conference. 1999 , 86, 2436-46	113
361	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 1999 , 82, 525-31	21
360	Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells. 1999 , 83, 409-14	3
359	Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors. 1999 , 25-79	367
358	Monoclonal antibodies. 1999 , 4, 355-365	
357	Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 1999 , 26, 781-90	31
356	Differential diagnosis of peri- and postmenopausal ovarian cysts. 1999 , 31, 123-32	10

355	Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. 1999 , 83, 201-6		16
354	Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. 1999 , 60, 510-5		59
353	Molecular aspects of ovarian cancer. Is gene therapy the solution?. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 109-33, viii	3.1	7
352	Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. 1999 , 246, 471-9		45
351	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. 2000 , 89, 383-90		90
350	Retinoids and ovarian cancer. 2000 , 185, 1-20		73
349	Role of erbB2 in breast cancer chemosensitivity. 2000 , 22, 673-80		97
348	Ovarian cancer: epidemiology, biology, and prognostic factors. 2000 , 19, 3-10		496
347	Molecular approaches to management of epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000 , 10, 2-7	3.5	10
346	The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. 2000 , 6, 189-95		146
345	DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. 2000 , 7, 703-6		64
344	Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. 2000 , 50, 219-23		14
343	Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. 2000 , 191, 93-105		25
342	Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. 2000 , 121, 26-32		34
341	DNA replication errors are frequent in mucinous cystadenocarcinoma of the ovary. 2000 , 117, 61-5		13
340	Ethanol enhances erbB-mediated migration of human breast cancer cells in culture. 2000 , 63, 61-9		36
339	E-Cadherin complex protein expression and survival in ovarian carcinoma. 2000 , 79, 362-71		34
338	Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. 2000 , 275, 24735-9		99

337	Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. 2000 , 18, 110-4	17
336	Analysis of serum ErbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer. 2000 , 152, 87-95	8
335	Monoclonal antibody therapy for solid tumors. 2000 , 26, 269-86	125
334	Expression and function of EGF-related peptides and their receptors in gynecological cancer--from basic science to therapy. 2000 , 20, 1-46	15
333	Liposome targeting to tumors using vitamin and growth factor receptors. 2000 , 60, 285-332	41
332	A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. 2001 , 24, 903-20	142
331	Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. 2001 , 84, 1528-34	31
330	Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. 2001 , 34, 227-32	15
329	Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. 2001 , 163, 131-9	70
328	DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. 2001 , 169, 155-64	98
327	Ovarian surface epithelium: biology, endocrinology, and pathology. 2001 , 22, 255-88	778
326	Cancer Genetics. 2001 , 445-456	
325	Transfection of the c-erbB2/neu gene upregulates the expression of sialyl Lewis X, alpha1,3-fucosyltransferase VII, and metastatic potential in a human hepatocarcinoma cell line. 2001 , 268, 3501-12	34
324	Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. 2001 , 47, 21-8	30
323	Correlation of p27 protein expression with HER-2/neu expression in breast cancer. 2001 , 30, 169-75	41
322	Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model. 2001 , 91, 529-37	19
321	Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. 2001 , 31, 3261-70	36
320	Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. 2001 , 80, 145-55	27

319	Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 2001 , 82, 273-8		57
318	Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. 2001 , 84, 1377-83		208
317	Changes in gene expression during progression of ovarian carcinoma. 2001 , 128, 1-6		120
316	Targeting HER2 in other tumor types. 2001 , 12 Suppl 1, S81-7		108
315	Trastuzumab in the treatment of HER2 positive breast cancer. 2001 , 7, 9-25		1
314	Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. 2001 , 276, 48679-92		150
313	Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. <i>Advances in Experimental Medicine and Biology</i> , 2000 , 465, 171-80	3.6	31
312	HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. 2002 , 168, 5900-6		111
311	Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. 2002 , 13, 949-56		22
310	Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. 2002 , 273, 95-106		32
309	Molecular aspects of ovarian cancer. 2002 , 16, 483-97		32
308	Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. <i>American Journal of Pathology</i> , 2002 , 160, 339-45	5.8	75
307	Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. 2002 , 36, 257-61		38
306	Clinical significance of PEA3 in human breast cancer. 2002 , 131, S222-5		18
305	Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. 2002 , 9, 407-13		10
304	c-erbB-2 is not a major factor in the development of colorectal cancer. 2002 , 86, 568-73		53
303	Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. 2002 , 86, 1449-56		179
302	Specific keynote: chemoprevention of ovarian cancer: the journey begins. 2003 , 88, S59-66; discussion S67-70		9

301	Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. 2003 , 88, 73-9		150
300	Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. 2003 , 442, 322-8		28
299	Clinicopathologic profile of gestational trophoblastic disease. 2003 , 115, 29-35		9
298	HER2/neu overexpression: has the AchillesRheel of uterine serous papillary carcinoma been exposed?. 2003 , 88, 263-5		36
297	Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. 2003 , 89, 99-104		14
296	Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. 2003 , 90, 629-36		22
295	Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. 2003 , 91, 231-40		24
294	Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. 2003 , 97, 2615-30		45
293	Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. 2003 , 98, 66-73		96
292	Neuregulin promotes autophagic cell death of prostate cancer cells. 2003 , 55, 147-57		20
291	Targeted therapy for epithelial ovarian cancer: current status and future prospects. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 701-34	3-5	39
290	Molecular similarities between primary peritoneal and primary ovarian carcinomas. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 749-55	3-5	26
289	Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines. 2003 , 16, 131-9		7
288	Tissue microarrays in drug discovery. 2003 , 2, 962-72		150
287	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. 2003 , 2, 50-7		49
286	Progress in ovarian cancer. 2003 , 1, 43-55		7
285	Prognostic factors in ovarian cancer: current evidence and future prospects. 2003 , 1, 127-145		14
284	EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. 2003 , 307, 653-9		12

283	Low effectiveness of DNA vaccination against HER-2/neu in ageing. 2003 , 21, 843-8	39
282	Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. 2003 , 278, 23107-17	195
281	Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. 2003 , 100, 9226-31	156
280	Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. 2005 , 242, 1-54	48
279	Current treatment options for endometrial cancer. 2004 , 4, 679-89	34
278	Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. 2004 , 279, 4339-45	90
277	Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. 2004 , 90, 2032-41	20
276	Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. 2004 , 14, 497-506	45
275	TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. 2004 , 91, 1916-23	23
274	The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. 2004 , 31, 75-82	50
273	Targeting the HER-kinase axis in cancer. 2004 , 31, 9-20	53
272	Estrogens and epithelial ovarian cancer. 2004 , 94, 25-32	117
271	Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. 2004 , 94, 735-9	15
270	Genomic analyses of primary and metastatic serous epithelial ovarian cancer. 2004 , 154, 16-21	24
269	Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. 2004 , 90, 1814-24	44
268	Overexpression of Her2/neu, estrogen and progesterone receptors in invasive micropapillary carcinoma of the breast. 2004 , 11, 301-6	14
267	Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. 2004 , 11, 249-59	25
266	Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. 2004 , 108, 71-7	122

265	Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. 2004 , 112, 492-501	42
264	Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. 2004 , 6, 786-95	96
263	Ovarian Carcinogenesis. 2004 , 591-612	5
262	Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer. 2004 , 625-645	
261	Analysis of potential prognostic factors in 111 patients with ovarian cancer. 2004 , 206, 97-106	23
260	3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. 2005 , 4, 333-338	
259	Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. 2005 , 192, 813-8	104
258	Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast. 2005 , 12, 189-95	34
257	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. 2005 , 24, 6174-84	28
256	Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. 2005 , 98, 24-30	80
255	Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. 2005 , 104, 1391-7	121
254	Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. 2005 , 104, 2417-29	81
253	Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. 2005 , 7, 158-70	20
252	Immunoprevention and immunotherapy of cancer in ageing. 2005 , 54, 93-106	36
251	Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. 2005 , 371, 141-51	16
250	Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. 2005 , 22, 915-22	3
249	Biological characterization of ovarian cancer: prognostic and therapeutic implications. 2005 , 16 Suppl 4, iv95-101	25
248	Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. 2005 , 12, 1324-32	31

247	Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. 2005 , 16, 1889-97		37
246	Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. 2005 , 92, 1729-36		21
245	Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. 2005 , 280, 8238-47		46
244	HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. 2005 , 68, 154-61		96
243	Purification and characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system. 2005 , 41, 68-76		7
242	Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. 2006 , 32, 180-90		106
241	Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). 2006 , 42, 2539-48		25
240	In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 2006 , 33, 333-47		47
239	HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours. 2006 , 4, 39-42		2
238	Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 145-51	3-5	25
237	Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 1, 200-6	3-5	11
236	Use of trastuzumab in the treatment of metastatic endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 1370-3	3-5	53
235	HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. <i>International Journal of Gynecological Cancer</i> , 2006 , 16, 1897-902	3-5	102
234	HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. 2006 , 48, 149-56		36
233	Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli. 2006 , 70, 78-84		15
232	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. 2006 , 33, 631-8		58
231	Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. 2006 , 100, 139-44		44
230	Requirement for CDK4 kinase function in breast cancer. 2006 , 9, 23-32		307

229	Hormonosensibilités des cancers ovariens <i>βithiaux</i> . 2006 , 57-70		
228	Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. 2006 , 407, 660-76		15
227	The N-terminal domains of neuregulin 1 confer signal attenuation. 2006 , 281, 27306-16		18
226	Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. 2006 , 5, 233-47		41
225	Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. 2007 , 282, 1265-80		74
224	Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. 2007 , 282, 19426-41		119
223	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. 2007 , 2, 225-238		1
222	Immunologic markers of cancer progression and prognosis. 2007 , 1, 439-50		
221	Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. 2007 , 6, 294-304		28
220	Endocrine signaling in ovarian surface epithelium and cancer. 2007 , 13, 143-62		65
219	Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. 2007 , 360, 363-9		10
218	Novel agents in ovarian cancer. 2007 , 16, 1227-39		9
217	[Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. 2007 , 128, 1-6		4
216	HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. <i>PLoS ONE</i> , 2007 , 2, e11387		116
215	Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. 2007 , 98, 380-6		20
214	The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007 , 17, 798-807	3-5	57
213	Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. <i>International Journal of Gynecological Cancer</i> , 2007 , 17, 1003-10	3-5	35
212	Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. 2007 , 36, 83-7		6

211	Histomorphological and immunohistochemical characterization of equine granulosa cell tumours. 2007 , 136, 167-76		32
210	Is Her-2/neu expressed in nonepithelial ovarian malignancies?. 2007 , 196, 79.e1-4		5
209	Anti-tumor immunity induced by an anti-idiotypic antibody mimicking human Her-2/neu. 2007 , 104, 1-11		15
208	Differences in radiosensitivity between three HER2 overexpressing cell lines. 2008 , 35, 1179-91		14
207	Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats. 2008 , 134, 337-44		4
206	Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. 2008 , 123, 2636-43		20
205	ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells. 2008 , 105, 875-84		21
204	HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 14-21	3.5	56
203	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. 2008 , 1785, 232-65		113
202	Pharmaceutical management of ovarian cancer : current status. 2008 , 68, 771-89		83
201	The promise and perils of targeted therapy of advanced ovarian cancer. 2008 , 74, 1-6		17
200	Small interfering RNA technology in pancreatic ductal epithelial cells: future cancer therapy. 2008 , 4, 249-256		
199	CCL16 enhances the CD8+ and CD4+ T cell reactivity to human HER-2 elicited by dendritic cells loaded with rat ortholog HER-2. 2008 , 21, 867-77		4
198	Ovaries. 2009 , 1356-1408		3
197	The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. 2009 , 87, 1-11		73
196	Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. 2009 , 113, 341-7		35
195	Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. 2009 , 190, 66-70		13
194	Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). 2009 , 151, 241-9		14

193	Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. 2009 , 101, 149-59		89
192	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 2009 , 36, 659-69		35
191	A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. 2009 , 27, 4826-33		27
190	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 109-15	3.5	10
189	Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. 2010 , 203, 162.e1-8		16
188	Higher sensitivity to paclitaxel versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. 2010 , 119, 140-5		13
187	Growth regulation and transformation of ovarian epithelium. 1993 , 71, 545-51		45
186	Genetic epidemiology of epithelial ovarian cancer. 1993 , 71, 566-72		44
185	The detection, treatment, and biology of epithelial ovarian cancer. 2010 , 3, 8		47
184	In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. 2010 , 102, 134-43		82
183	Silencing of the CCNB1, Her2, and PKC genes by small interfering RNA differently retards the division of different human cancer cell lines. 2010 , 44, 89-96		1
182	Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. 2010 , 2, 913-54		20
181	Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. <i>Cancer Research</i> , 2010 , 70, 2686-96	10.1	25
180	Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. 2010 , 2010, 791603		37
179	Her-2/neu expression in testicular cancer—a retrospective analysis in 57 cases. 2010 , 76, 1266.e6-9		1
178	Current treatment and clinical trials in ovarian cancer. 2010 , 19, 521-34		17
177	Pertuzumab for the treatment of ovarian cancer. 2010 , 10, 1113-20		24
176	Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. 2011 , 54, 8030-50		118

175	Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma. 2011 , 2, 399-403	6
174	Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. 2011 , 242, 46-54	71
173	Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. 2011 , 30, 347-53	23
172	Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. 2011 , 64, 1097-101	26
171	Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. 2011 , 17, 4052-62	75
170	In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. 2011 , 21, 173-8	67
169	SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer. 2011 , 18, 859-70	2
168	erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. 2011 , 2011, 128295	9
167	Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. 2012 , 32, 2880-93	43
166	Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. 2012 , 12, 41-9	26
165	The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells. 2012 , 287, 23171-83	34
164	Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. 2012 , 10, 148	126
163	Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. 2012 , 20, 6171-80	18
162	EGFR/HER-targeted therapeutics in ovarian cancer. 2012 , 4, 447-69	36
161	High-sensitivity detection of breast tumors in vivo by use of a pH-sensitive near-infrared fluorescence probe. 2012 , 17, 076028	22
160	EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?. <i>PLoS ONE</i> , 2012 , 7, e34071	3-7 48
159	Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. 2012 , 61, 991-1003	28
158	A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. 2012 , 124, 569-74	60

157	RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. 2012 , 124, 589-97	12
156	Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer. 2013 , 6, 2	6
155	DNA copy gains of tumor-related genes in vestibular schwannoma. 2013 , 270, 2433-8	1
154	Receptor-directed chimeric toxins created by sortase-mediated protein fusion. 2013 , 12, 2273-81	34
153	The expression of HER-2/neu gene in colon cancer tissues and its clinical significance. 2013 , 12, 492-497	
152	Targeting HER2-positive cancer cells with receptor-redirectioned anthrax protective antigen. 2013 , 7, 440-51	50
151	Target-specific nanoparticles containing a broad band emissive NIR dye for the sensitive detection and characterization of tumor development. 2013 , 34, 160-70	48
150	HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. 2013 , 17, 85-99	129
149	A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. 2013 , 24, 145-52	68
148	HER-2 as a Prognostic and Predictive Biomarker in Cancer. 2013 , 77-120	
147	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. 2013 , 4, 679-85	4
146	Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas. 2013 , 6, 1065-71	1
145	Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. 2014 , 111, 1750-6	22
144	[Pertuzumab and solid tumors: perspectives]. 2014 , 101, 1114-21	2
143	Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. 2014 , 135, 142-8	22
142	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. 2014 , 2014, 852748	439
141	When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. 2014 , 3, 53-78	25
140	Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer. 2014 , 32, 1012-8	5

139	Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. 2014 , 35, 33-8	5
138	Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. 2014 , 18, 137-51	24
137	Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. 2014 , 41, 947-56	21
136	Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes. 2014 , 13, 212-27	30
135	Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma. 2014 , 34, 1225-32	11
134	Molecular Targets in Gynecologic Cancers. 2014 , 1-17	
133	Pattern Recognition of HER-2 in Whole Blood Samples Using Stochastic Microsensors. 2015 , 4, S3067-S3070	3
132	Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. 2015 , 9, 2211-2217	3
131	PRP4K is a HER2-regulated modifier of taxane sensitivity. 2015 , 14, 1059-69	18
130	HER-2-based design of pertuzumab mimetic peptides. 2015 , 41, 1298-1307	1
129	Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism. 2015 , 25, 758-62	5
128	Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. 2015 , 36, 5505-13	4
127	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. 2015 , 33, 177-86	20
126	Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging. 2015 , 11, 2051-60	28
125	Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. 2015 , 138, 620-6	22
124	Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study. 2015 , 14, 3519-29	10
123	Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli. 2015 , 116, 66-74	13
122	Breast cancer therapy and cardiovascular risk: focus on trastuzumab. 2015 , 11, 223-8	27

121	Development of a prelabeling approach for a targeted nanochelator. 2015 , 305, 161-167		2
120	PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. 2015 , 113, 1020-6		27
119	Lipid rafts, KCa/ClCa/Ca ²⁺ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?. 2015 , 1848, 2603-20		43
118	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. 2015 , 28, 428-36		25
117	Synthesis and Preliminary Biological Evaluations of Fluorescent or Promethium Labeled Trastuzumab-Polyethylenimine. <i>Biomedicines</i> , 2015 , 4,	4.8	10
116	Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma. 2016 , 11, 3028-3032		3
115	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. 2017 , 405, 123-143		6
114	Metabolic Regulation of Apoptosis in Cancer. 2016 , 327, 43-87		96
113	A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. 2016 , 4, 257-274		6
112	Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus. 2016 , 5, 44		3
111	HER2/neu, p53, MIB1 and PAX8 immunoeexpression in Primary Serous Fallopian Tube Carcinomas. 2016 , 49, 219-225		
110	A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer. 2016 , 5, e1166323		16
109	The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria. 2016 , 8, 9-13		1
108	Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. 2016 , 37, 3913-23		12
107	Peptides for tumor-specific drug targeting: state of the art and beyond. 2017 , 5, 4348-4364		28
106	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. 2017 , 34, 91		14
105	Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. 2017 , 44, 1296-1305		23
104	Electrohydrodynamic-Induced SERS Immunoassay for Extensive Multiplexed Biomarker Sensing. 2017 , 13, 1602902		63

103	Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer. 2017 , 5, 7082-7098		28
102	Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. 2017 , 7, 4204		19
101	Influence of Label and Charge Density on the Association of the Therapeutic Monoclonal Antibodies Trastuzumab and Cetuximab Conjugated to Anionic Fluorophores. 2017 , 18, 101-110		5
100	Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017 , 8, 75528-75543	3-3	4
99	Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. 2018 , 420, 168-181		3
98	Receptor Occupancy Imaging Studies in Oncology Drug Development. 2018 , 20, 43		9
97	Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. <i>PLoS ONE</i> , 2018 , 13, e0200664	3-7	8
96	Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex nanoparticles for docetaxel delivery in ovarian cancer. 2018 , 13, 493-504		26
95	The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. <i>PLoS ONE</i> , 2018 , 13, e0191972	3-7	31
94	Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment.. 2019 , 9, 23894-23907		7
93	Efficacy of afatinib in a amplification-positive endometrioid adenocarcinoma patient- a case report. 2019 , 12, 5305-5309		3
92	Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles. 2019 , 131, 10731-10735		11
91	Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/E-catenin Signaling. 2019 , 18, 1708-1720		9
90	A Role of PET Agents Beyond FDG in Gynecology. 2019 , 49, 501-511		1
89	Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. 2019 , 11,		23
88	Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles. 2019 , 58, 10621-10625		82
87	Spectroscopic exploration of binding of new imidazolium-based palladium(II) salicylate complexes with CT-DNA as anticancer agents against HER2/neu overexpression. 2019 , 1191, 118-128		13
86	Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. 2019 , 178, 199-207		43

85	HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFB-dependent way. 2019 , 39,			3
84	Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. 2019 , 13, 132-152			14
83	CAR T-Cell Therapy for CNS Malignancies. 2020 , 165-198			
82	Natural Born Killers: NK Cells in Cancer Therapy. 2020 , 12,			18
81	The Potential Usefulness of Tc-HYNIC-(Ser)-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice. 2020 ,			1
80	Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors. 2020 , 10, 2343			1
79	CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data. 2021 , 52, 1-10			5
78	The unpredictable carbon nanotube biocorona and a functionalization method to prevent protein biofouling. 2021 , 19, 129			0
77	Expression of HER2/neu Receptor in Epithelial Ovarian Cancers: An Immunohistochemical Pilot Study in Central India. 2021 , 19, 1			
76	A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. 2021 , 13,			5
75	Differential oligonucleotide activity in cell culture versus mouse models. 1997 , 209, 124-37; discussion 137-41			3
74	Ovary. 2002 , 304-320			1
73	Biomarker targets and novel therapeutics. <i>Cancer Treatment and Research</i> , 2009 , 149, 85-105	3.5		3
72	Intraperitoneal immunotherapy of cancer: a review of options for treatment. <i>Cancer Treatment and Research</i> , 1996 , 82, 13-40	3.5		1
71	Towards an immunotherapy for p185HER2 overexpressing tumors. <i>Advances in Experimental Medicine and Biology</i> , 1994 , 353, 83-94	3.6		2
70	Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. <i>Cancer Treatment and Research</i> , 1994 , 71, 161-91	3.5		20
69	Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. <i>Cancer Treatment and Research</i> , 1992 , 63, 15-60	3.5		29
68	Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. <i>Cancer Treatment and Research</i> , 1992 , 61, 193-211	3.5		23

67	c-erb B2 amplification and overexpression in human tumors. <i>Cancer Treatment and Research</i> , 1991 , 161-179	3.5	23
66	Prognostic factors in ovarian cancer. <i>Cancer Treatment and Research</i> , 1998 , 95, 287-352	3.5	15
65	Molecular and biological factors in the pathogenesis of ovarian cancer. 1995 , 77-87		2
64	The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). <i>Cancer Treatment and Research</i> , 2002 , 107, 3-28	3.5	35
63	Normal ovarian surface epithelium. <i>Cancer Treatment and Research</i> , 2002 , 107, 161-83	3.5	22
62	T-Cell and NK-Mediated Surveillance of Cancer. 1998 , 249-271		1
61	Epidermal Growth Factor-Related Peptides in Endocrine Neoplasias. 2000 , 137-191		1
60	Tumor-stromal cytokine interactions in ovarian neoplasms. 1995 , 74, 181-90		5
59	IgE immunotherapy against cancer. 2015 , 388, 109-49		12
58	Tyrosine kinase inhibitors and cancer therapy. <i>Recent Results in Cancer Research</i> , 2007 , 172, 25-44	1.5	4
57	Comparative studies of molecular mechanisms of tumorigenesis in herbicide-exposed bivalves. 1996 , 29-43		2
56	Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. 1997 , 259, 189		3
55	Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. 2004 , 385-398		1
54	EGF Family Receptors and Their Ligands in Human Cancer. 1998 , 113-165		8
53	Targeting HER-2/neu-Overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome. 1999 , 357-377		3
52	E1A Cancer Gene Therapy. 2002 , 465-477		4
51	Epithelial Ovarian Cancer. 2007 , 313-367		7
50	Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene. 1998 , 325-345		2

- 49 Ovarian cancer: markers of response. *International Journal of Gynecological Cancer*, **2009**, 19 Suppl 2, S21-9 3.5 18
- 48 Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. *PLoS ONE*, **2013**, 8, e75288 3.7 8
- 47 Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. *Oncotarget*, **2016**, 7, 13013-30 3.3 5
- 46 The Genetic Etiology of Sporadic Ovarian Cancer. **2003**, 139-155
- 45 The Long-Term Management of Ovarian Cancer. **2003**, 467-476
- 44 Novel therapies in gynaecological cancer. **2011**, 554-565
- 43 In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells. *Oligonucleotides*, 121102072334007
- 42 Ovarian Cancer: Advances in Management. *Hematology/Oncology Clinics of North America*, **1991**, 5, 1285-1302
- 41 Ovarian Carcinoma: Tumor- and Molecular Biology. **1993**, 7-19 2
- 40 Therapeutic Opportunities Involving Cellular Oncogenes. **1993**, 213-222
- 39 Directions in the Design of Clinical Trials, Present and Future. **1993**, 313-329
- 38 Immunohistochemische Untersuchungen über das c-erbB-2 Protein am Ovarialkarzinom. **1993**, 951-952
- 37 Die Bedeutung der c-erbB-2 und c-myc Onkogen-Expression für die Prognose beim Ovarialkarzinom. **1993**, 946-948
- 36 Hereditary and familial ovarian cancer. *Recent Results in Cancer Research*, **1994**, 136, 133-45 1.5
- 35 Signal transduction therapy: a new paradigm. **1995**, 257-269
- 34 Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies. **1995**, 111-138 1
- 33 Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor- α **1995**, 109-113
- 32 Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization. **1995**, 347-356

31	In vitro priming to tumor-associated proteins. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 417, 503-9	3.6	
30	Malignancies of the Ovaries. <i>Medical Radiology</i> , 1997 , 297-396	0.2	
29	References. 1997 , 215-326		
28	Pharmacologic advantages of anthracyclines encapsulated in poly-ethylene-glycol coated Stealth liposomes: Potential for tumor targeting. 1998 , 259-274		1
27	HER-2/neu in Breast Cancer: A Possible Means of Therapy?. 1998 , 121-136		
26	Biological therapy for gynecologic malignancies. <i>Cancer Treatment and Research</i> , 1998 , 95, 115-47	3.5	
25	Advances in the pathology of gynecologic cancer. <i>Cancer Treatment and Research</i> , 1998 , 95, 353-76	3.5	
24	Factors Influencing Tumor-Selective Localization of Antibody Conjugates. 1999 , 39-96		
23	Gynecologic Cancers. 1999 , 199-210		
22	Breast Cancer and Immunosenescence. 2018 , 1-31		
21	Breast Cancer and Immunosenescence. 2019 , 2115-2145		
20	Evaluation of Serum Human Epididymis Protein 4 Levels in Women with Polycystic Ovary Syndrome. <i>Cureus</i> , 2019 , 11, e5736	1.2	
19	The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. <i>Biomedicines</i> , 2021 , 9,	4.8	
18	Ovarian Cancer. 1999 , 1-53		
17	Breast Cancer and Immunosenescence. 2009 , 1139-1163		
16	Antimetastasis. 2005 , 287-298		
15	Targeted Therapy in Epithelial Ovarian Cancer. 2008 , 261-269		
14	Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. <i>EMBO Journal</i> , 1993 , 12, 961-71	13	65

13	Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. <i>American Journal of Pathology</i> , 1992 , 140, 23-31	5.8	29
12	K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. <i>American Journal of Pathology</i> , 1991 , 139, 777-85	5.8	128
11	Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. <i>American Journal of Pathology</i> , 1993 , 142, 733-41	5.8	34
10	A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. <i>American Journal of Human Genetics</i> , 1994 , 55, 666-77	11	52
9	New frontiers in ovarian cancer diagnosis and management. <i>Yale Journal of Biology and Medicine</i> , 1991 , 64, 127-41	2.4	8
8	Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. <i>Biologics: Targets and Therapy</i> , 2007 , 1, 367-76	4.4	16
7	Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division. <i>Acta Naturae</i> , 2011 , 3, 29-39	2.1	1
6	OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES. 2008 , 87, 249-260		5
5	HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES. 2007 , 86, 297-308		2
4	Profiling serum HER-2/NEU in prostate cancer. <i>Hippokratia</i> , 2013 , 17, 108-12	0.4	4
3	A trispesific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.. <i>Nature</i> , 2022 ,	50.4	8
2	Predicting Response to Anthracyclines in Ovarian Cancer.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	
1	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. <i>Antioxidants</i> , 2022 , 11, 1195	7.1	0